Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glioma].

Toshihiko Wakabayashi1, Atsushi Natsume, Jun Yoshida

  • 1Center for Genetic and Regenerative Medicine, Nagoya University Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EXPRESS: Toll Like Receptor 4 (TLR4) in Neuroinflammation: From Acute Hemorrhagic Stroke to Chronic Neurodegeneration.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer.

Cancer diagnosis & prognosis·2026
Same author

A diagnostic pitfall of CT calcium scoring in paradoxical low-flow, low-gradient severe aortic stenosis with rheumatic morphology: a case report.

European heart journal. Case reports·2026
Same author

Rare Extrahepatic Metastasis of Hepatocellular Carcinoma to the Left Triangular Ligament: A Case Report.

Surgical case reports·2026
Same author

The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic cancer: a retrospective study.

World journal of surgical oncology·2026
Same author

High-Throughput Heterospheroid-Based Screening Identifies Drugs That Reprogram Tumor-Associated Macrophages.

Journal of immunology research·2026
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Interferon-beta shows efficacy in treating brain tumors like glioma, alone or with chemo-radiotherapy. New combinations and gene therapy show promise for improved brain tumor treatment outcomes.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Immunotherapy

Background:

  • Interferon-beta is an established therapeutic agent for brain tumors, particularly glioma.
  • Its efficacy has been demonstrated both as a monotherapy and in combination with chemotherapy and radiotherapy.
  • Recent advancements focus on enhancing its therapeutic potential through novel combination regimens and drug delivery systems.

Purpose of the Study:

  • To review the current clinical applications of interferon for brain tumor treatment.
  • To highlight recent improvements in combination therapies involving interferon-beta.
  • To discuss the potential of interferon-beta gene therapy for malignant brain tumors.

Main Methods:

  • Review of existing clinical data on interferon-beta for brain tumor treatment.

Related Experiment Videos

  • Analysis of combination regimens including chemotherapy (e.g., ACNU/MCNU, temozolomide) and radiotherapy.
  • Evaluation of interferon-beta gene therapy using liposomal drug delivery systems.

    • Main Results:

    • Interferon-beta has shown effectiveness in treating brain tumors, including glioma.
    • Combination therapy with chemotherapy and radiotherapy improves efficacy rates.
    • Interferon-beta gene therapy has demonstrated clinical safety and effectiveness.

    Conclusions:

    • Interferon-beta remains a valuable option for brain tumor treatment.
    • Optimized combination therapies and gene therapy approaches are expected to improve outcomes for malignant brain tumors.
    • Further clinical trials are anticipated to solidify the role of novel interferon-based strategies.